News and features

Scientists from The Institute of Cancer Research (ICR), London, are taking part in a groundbreaking new set of brain cancer clinical trials designed to improve survival and quality of life for people with glioblastoma.

Researchers have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen in patients.

In a significant advancement, cancer researchers have found a long-sought way to overcome a critical design barrier in the generation of small-molecule chemical tools and drugs that work by targeted protein degradation.

The NIHR has announced a £13.7 million investment into research to develop new brain tumour treatments in the UK. The funding will establish the NIHR Brain Tumour Research Consortium – a national partnership uniting hospitals, universities, cancer centres and charities, along with patients. This is a coordinated UK-wide effort, which will involve the ICR's scientists, aims to transform brain cancer treatment.

The Royal Marsden Hospital, St George's Hospital and King's College Hospital with The Institute of Cancer Research, London, as the South London Paediatric Neuro-Oncology Network, has announced that it has been designated a Tessa Jowell Centre of Excellence for Children.

A recent study on an aggressive type of brain cancer has significantly advanced the understanding of the spectrum of tumours that occur in teenagers and young adults (TYA).

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned.

Scientists at The Institute of Cancer Research, London, are partnering with Revolver Therapeutics to accelerate the development of pioneering drugs for treating incurable childhood brain tumours.

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma, a common type of adult brain tumour, rely on a specific enzyme for survival and that inhibiting this enzyme leads to the death of the cells.

A new imaging technique could mean patients with aggressive glioblastomas benefit from cutting edge immunotherapy treatments, according to researchers.

A pioneering research study, led by researchers at The Institute of Cancer Research and The Royal Marsden, which will allow brain cancer patients to access drugs that are precisely targeted to their disease and swap to different treatments if needed, has launched in the UK.

Scientists have uncovered a treasure trove of information about the genetic causes of brain cancer in the largest-ever study of the disease.